Skylar Jeremias

A meta-analysis of published literature confirmed that N-aceteylcysteine, a cough medication, was effective at improving symptoms and lung function of patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD).

Examination of surgical wound fluids revealed several peptides and proteins that could be useful in identifying biomarkers for wound healing and infection, potentially allowing providers to better diagnose and treat infections.

A lack of consensus for the term “immunocompromised” suggests that studies demonstrating the effectiveness of infection prevention in surgical patients at a high risk of wound infection may have limited relevancy.

An algorithm influenced by cough sound recognition and symptom reporting conducted using a smartphone was found to be effective at diagnosing patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD).

Despite positive data showing that negative pressure wound therapy (NPWT) can help accelerate wound healing for neck and head wounds, investigators of a review found that the presence of certain comorbidities may slow healing times.

Topical and intravenous tranexamic acid (TXA) were found to significantly reduce blood loss compared with placebo in patients who have undergone bone surgery, suggesting that both administration methods may be effective at promoting wound healing.

A recent study examined the prevalence and characteristics of 3 atypical pathogens responsible for respiratory tract infections in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD), as well as evaluated optimal detection methods.

Recent reports document new COVID-19 guidance for people with psoriatic disease, positive safety and efficacy results for guselkumab, and findings linking the C-Jun protein with psoriasis.

The latest news in the rheumatology space revealed potential biomarkers for differentiating psoriatic arthritis (PsA) from rheumatoid arthritis (RA), as well as other rheumatology news reported across MJH Life Sciences™.

Highlighting the latest inflammation-related news reported across MJH Life Sciences™.

Validity assessments revealed that 2 algorithms utilizing administrative claims data and electronic medical records were accurate at identifying moderate and severe events signaling acute exacerbation of chronic obstructive pulmonary disease (AECOPD).

A report from Xcenda showed that biosimilars for 8 blockbuster reference biologics have successfully kept drug prices from increasing by an average of 56%, restoring the possibility that biosimilars could achieve significant discounts despite facing several barriers to uptake.

Older adults with chronic obstructive pulmonary disease (COPD) identified factors likely to encourage or discourage patients from utilizing different technologies to track and improve physical activity.

A panel of health care professionals reviewed published literature to develop a recommendation guide to advise providers on best practices when considering vaccinations for children with atopic dermatitis (AD) on dupilumab.

A study evaluating independent risk factors for invasive pulmonary aspergillosis (IPA) in hospitalized patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) validated a potential model that could help providers diagnose IPA earlier.

Investigators quelled concerns regarding whether patients with chronic obstructive pulmonary disease (COPD) would be likely to use eHealth tools after finding that most had internet access and were regular users of information technology.

Three recent conferences yielded new data on which treatment therapies are providing substantial benefits to patients and which ones are demonstrating more lackluster results.

Real-world data confirmed the clinical effectiveness of Celltrion Healthcare’s rituximab biosimilar (Truxima, CT-P10) in patients with diffuse large B-cell lymphoma (DLBCL).

Patients with ankylosing spondylitis taking secukinumab saw improvements in enthesitis, and some achieved complete resolution, suggesting the drug could be a viable option for patients intolerant of or unresponsive to other enthesitis-improving medications.

Treatable traits associated with the decline in lung function and quality of life (QOL) in patients with chronic obstructive pulmonary disease (COPD) were detected in a longitudinal study, highlighting targets that physicians can address to better individualize COPD management.

A study examining how US biosimilar uptake has evolved found that biosimilars launched more recently have seen better uptake than biosimilars that have been on the market for a longer period.

Variances between sex and age were found among patients with chronic obstructive pulmonary disease (COPD) with a viral infection who visited the emergency department (ED) visit or were hospitalized, highlighting the role that these factors play.

Physical frailty affects a large proportion of patients with chronic obstructive pulmonary disease (COPD) and chronic respiratory failure and current tools for detection may be inadequate, according to a recent report.

Celltrion Healthcare’s high-concentration adalimumab biosimilar demonstrated comparable safety, efficacy, and immunogenicity profiles to the reference product for up to a year, providing further evidence supporting use of the product.

Abstracts from the ATS 2021 International Conference addressed patient decision-making frameworks for seeking care for chronic obstructive pulmonary disease (COPD) and tactics used to assist hospitals in implementing readmission reduction plans.

Abstracts from the ATS 2021 International Conference provided some insight into tactics that could improve the effectiveness of pulmonary rehabilitation programs in patients with chronic obstructive pulmonary disease (COPD).

Some recent oncology news includes research into factors impacting the well-being of childhood cancer survivors; whether COVID-19 accommodations will last post-pandemic; and a possible new therapy for patients with polycythemia vera.

Sandoz Canada launches its sixth biosimilar, an anticoagulant used to treat deep vein thrombosis, on the Canadian market.

A literature review sheds light on cancer risk factors and suboptimal screening levels that persist in the United States among certain racial, ethnic, and socioeconomic groups, despite a steady decline in cancer deaths and smoking prevalence.

Posters presented at the ATS 2021 International Conference noted some ways clinical characteristics associated with patients with chronic obstructive pulmonary disease (COPD) differ based on different demographics and smoking status.